Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Create a free account to read 3 full reports each month — plus a 14-day Pro trial. Get started →
Walmart Inc.
WMTConsumer StaplesGenerated Jul 5, 2026, 08:09 PM UTC
WMT (Walmart Inc.) analytical snapshot. Revenue grew +6.0% YoY to $648.13B. 5-year revenue CAGR +4.3%; 10y CAGR +3.3%. Net margin at 2.39% (contracting ▼). Market cap $890.03B at $111.84 per share. Trailing P/E 58.55, P/S 1.37, P/B 9.44. EV/Operating income ≈ 33.97 (EV $917.47B). Risk: Elevated. Macro: Risk-on · Supportive. Composite analytical score -25 (data confidence 82%). Descriptive analytics from public filings — not investment advice.
Market cap
$890.03B
7.96B shares
Price
$111.84
NMS
P/E (ttm)
58.55
Revenue (FY)
$648.13B
YoY +6.0%
Net margin
2.39%
▼ 0.02pp
Free cash flow
$15.12B
2.33% margin
Risk level
Elevated
Free SEC analysis
— computed from SEC filings, free to readFree previewFundamentals Analyst
Fundamentals
Fundamentals Analyst
score 10Stable
80% conf
Revenue grew +6.0% YoY to $648.13B. 5-year revenue CAGR +4.3%; 10y CAGR +3.3%. Net margin at 2.39% (contracting ▼).
- Revenue grew +6.0% YoY to $648.13B.
- 5-year revenue CAGR +4.3%; 10y CAGR +3.3%.
- Net margin at 2.39% (contracting ▼).
- Return on equity 17.04%, ROA 6.15%, ROIC 21.27%.
- Gross margin 0.00%, operating margin 4.17%.
- Free cash flow margin 2.33% ($15.12B).
- Net income up ▲ +32.8% YoY.
- Debt/equity 0.40, current ratio 0.77, net debt $27.44B.
- Asset turnover 2.24 — capital efficiency.
Revenue (FY)
$648.13B
YoY +6.0%
Net margin
2.39%
▼ 0.02pp
ROE
17.04%
ROA 6.15%
ROIC
21.27%
EPS (diluted)
$1.91
FY2026
Free cash flow
$15.12B
2.33% margin
Debt / equity
0.40
Cash $10.73B
Current ratio
0.77
Equity $94.33B
Annual fundamentals — up to 10 years (SEC 10-K, US-GAAP)
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2017 | $485.65B | — | 0.00 | 5.59 | 3.37 | $16.39B | 20.32 |
| 2018 | $482.13B | -0.7% | 0.00 | 5.00 | 3.05 | $16.07B | 18.89 |
| 2019 | $485.87B | +0.8% | 0.00 | 4.69 | 2.81 | $21.05B | 17.52 |
| 2020 | $500.34B | +3.0% | 0.00 | 4.08 | 1.97 | $18.29B | 13.60 |
| 2021 | $514.40B | +2.8% | 0.00 | 4.27 | 1.30 | $17.41B | 8.93 |
| 2022 | $523.96B | +1.9% | 0.00 | 3.93 | 2.84 | $14.55B | 18.39 |
| 2023 | $559.15B | +6.7% | 0.00 | 4.03 | 2.42 | $25.81B | 16.23 |
| 2024 | $572.75B | +2.4% | 0.00 | 4.53 | 2.39 | $11.07B | 17.83 |
| 2025 | $611.29B | +6.7% | 0.00 | 3.34 | 1.91 | $11.98B | 13.93 |
| 2026 | $648.13B | +6.0% | 0.00 | 4.17 | 2.39 | $15.12B | 17.04 |
Quarterly revenue trend (last 6 quarters, SEC 10-Q)
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Apr 30, 2025 | $165.61B | +2.5% | — | 2.71% |
| Jul 31, 2025 | $343.01B | +3.7% | +107.1% | 3.36% |
| Jul 31, 2025 | $177.40B | -46.4% | -48.3% | 6.49% |
| Oct 31, 2025 | $522.51B | +4.4% | +194.5% | 3.38% |
| Oct 31, 2025 | $179.50B | -64.1% | -65.6% | 9.84% |
| Apr 30, 2026 | $177.75B | +7.3% | -1.0% | 3.00% |
Revenue (annual, SEC 10-K)
2017: 485,651
2018: 482,130
2019: 485,873
2020: 500,343
2021: 514,405
2022: 523,964
2023: 559,151
2024: 572,754
2025: 611,289
2026: 648,125
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Profitability trends (%)
GrossOperatingNet
Free cash flow (annual)
2017: 16,390
2018: 16,075
2019: 21,054
2020: 18,286
2021: 17,409
2022: 14,550
2023: 25,810
2024: 11,075
2025: 11,984
2026: 15,120
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Sources:SEC EDGAR — Company Facts (XBRL)
Free previewRegulatory Analyst
Filings & Ownership
Regulatory Analyst
score 30Improving
80% conf
Latest annual report (10-K) filed Mar 13, 2026. Latest quarterly report (10-Q) filed May 29, 2026. 5 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Mar 13, 2026.
- Latest quarterly report (10-Q) filed May 29, 2026.
- 5 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference Walmart Inc.; broad institutional reporting.
- Recent filers include Wiser Advisor Group LLC, Silver Grove Financial Group, Inc., Trivant Custom Portfolio Group, LLC.
- 4 recent 13D activist/beneficial-ownership filings — potential catalyst.
- 16 recent 13G passive institutional ownership notices.
Latest 10-K
Mar 13, 2026
Annual report
Latest 10-Q
May 29, 2026
8-K (recent)
5
Insider net
—
0B/0S
13F filers
10k+
Activist 13D
4
Recent 13F institutional filers (SEC EDGAR full-text)
| Filer | Form | Filed |
|---|---|---|
| Wiser Advisor Group LLC | 13F-HR | May 16, 2024 |
| Silver Grove Financial Group, Inc. | 13F-HR | Feb 13, 2026 |
| Trivant Custom Portfolio Group, LLC | 13F-HR | Apr 21, 2025 |
| Silver Grove Financial Group, Inc. | 13F-HR | Feb 17, 2026 |
| Saranac Partners Ltd | 13F-HR | Dec 5, 2025 |
Recent 8-K material events
| Date | Form | Description |
|---|---|---|
| Jun 5, 2026 | 8-K | 8-K |
| May 21, 2026 | 8-K | 8-K |
| Apr 30, 2026 | 8-K | 8-K |
| Mar 27, 2026 | 8-K | 8-K |
| Mar 13, 2026 | 8-K | 8-K |
Free previewSEC Filing Analyst
SEC Filing Deep-Analysis
SEC Filing Analyst
score -43Deteriorating
66% conf
3 risk signal(s), 1 positive signal(s), 2 watch item(s) detected from XBRL filing diff analysis. Revenue grew +6.0% but receivables grew +18.9% — the receivables-to-revenue gap suggests growth may be partially driven by extended credit terms rather than genuine demand. If DSO continues to rise, a revenue reversal or bad-debt charge could follow.
- Receivables outpacing revenue: Accounts receivable grew +18.9% YoY vs revenue growth of +6.0%. The +12.9% spread suggests extended credit terms, channel stuffing risk, or collection deterioration. Investigate the allowance for doubtful accounts and DSO trend.
- Material weakness in internal controls: The term "material weakness" appears in 22 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
- NEW: Restatement of financial statements in latest filing: The term "restate" "financial statements" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 17 filing(s).
- Operating cash flow exceeds net income: OCF is 2.30x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
- NEW: Impairment charge: Impairment charge appears in recent filings but not in the prior 24-month period. Monitor for materiality.
- NEW: Off-balance sheet arrangements: Off-balance sheet arrangements appears in recent filings but not in the prior 24-month period. Monitor for materiality.
- Endogenous analysis: Revenue grew +6.0% but receivables grew +18.9% — the receivables-to-revenue gap suggests growth may be partially driven by extended credit terms rather than genuine demand. If DSO continues to rise, a revenue reversal or bad-debt charge could follow.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 3 new risk-language term(s) detected in filing text: Restatement of financial statements, Impairment charge, Off-balance sheet arrangements.
- Ongoing high-severity risk language: Material weakness in internal controls.
Revenue
$648.13B
+6.0% YoY
Operating income
$27.01B
+32.2% YoY
Net income
$15.51B
+32.8% YoY
Operating cash flow
$35.73B
+23.9% YoY
Capex
$20.61B
+22.2% YoY
Total assets
$252.40B
+3.8% YoY
Long-term debt
$36.00B
-9.0% YoY
Cash & equivalents
$9.04B
-8.4% YoY
Filing quality score
70/100
stable
SEC XBRL metric changes (latest annual vs prior)
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $611.29B | $648.13B | $36.84B | +6.0% |
| Operating income | $20.43B | $27.01B | $6.58B | +32.2% |
| Net income | $11.68B | $15.51B | $3.83B | +32.8% |
| Operating cash flow | $28.84B | $35.73B | $6.88B | +23.9% |
| Capex | $16.86B | $20.61B | $3.75B | +22.2% |
| Total assets | $243.20B | $252.40B | $9.20B | +3.8% |
| Long-term debt | $39.58B | $36.00B | $-3.58B | -9.0% |
| Cash & equivalents | $9.87B | $9.04B | $-830.0M | -8.4% |
| Stockholders equity | $83.86B | $91.01B | $7.15B | +8.5% |
| Inventory | $54.89B | $56.44B | $1.54B | +2.8% |
| Accounts receivable | $3.70B | $4.40B | $700.0M | +18.9% |
| SG&A expense | $127.14B | $130.97B | $3.83B | +3.0% |
| Interest expense | $1.79B | $2.26B | $472.0M | +26.4% |
XBRL disclosure changes (new vs dropped concepts)
| Type | Concepts |
|---|---|
| Removed | AccountsReceivableNet, AccrualForTaxesOtherThanIncomeTaxesCurrent, AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment, AdvertisingExpense, AllocatedShareBasedCompensationExpense, CommonStockParOrStatedValuePerShare, CommonStockSharesAuthorized, CurrentFederalTaxExpenseBenefit, CurrentForeignTaxExpenseBenefit, CurrentIncomeTaxExpenseBenefit |
Risk language in filing text (EDGAR full-text search)
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Material weakness in internal controls | high | 22 | 2 | Ongoing |
| Restatement of financial statements | high | 17 | 0 | NEW |
| Impairment charge | medium | 10 | 0 | NEW |
| Restructuring | medium | 58 | 5 | Ongoing |
| Off-balance sheet arrangements | medium | 17 | 0 | NEW |
| Related party transactions | low | 36 | 0 | NEW |
Filing signal breakdown
Red flags: 3
Positive: 1
Watch: 2
Red flags
Positive
Watch
Unlock the rest
- ProValuationMarket cap $890.03B at $111.84 per share.
- ProPrice & TechnicalsPrice $111.84 — downtrend (below 200-DMA); 1-month momentum negative.
- ProMacro & RatesMarket regime: Risk-on · Supportive.
- ProRisk ScorecardComposite risk: Elevated.
This content is for Pro subscribers
Unlock the full breakdown from all analysts — valuation (DCF & Graham), price & technicals, macro, risk scorecard, and 13F/13D ownership flow — plus your research workspace.
3 sections free · 4 Pro sections locked · composite -25
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Walmart Inc. is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Macro regime
Risk-on · Supportive
Yield curve
Normal
VIX
16.59
Fed funds
3.63%
CPI YoY
+4.2%
Analytical read
deterministic previewLatest annual report (10-K) filed Mar 13, 2026..
Risk
Elevated
Macro regime
Risk-on · Supportive
Macro exposure
Neutral
Descriptive analytics from public filings and macro data — not investment advice.
Peer comparison
Defensive groupHow WMT stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| Bristol-Myers Squibb BMY | 12 | Neutral |
| Cigna Group CI | 9 | Neutral |
| Procter & Gamble PG | 9 | Neutral |
| UnitedHealth Group UNH | 6 | Neutral |
| CVS Health Corp. CVS | 6 | Neutral |
| Eli Lilly & Co. LLY | 3 | Neutral |
| Colgate-Palmolive CL | 1 | Neutral |
| Coca-Cola Co. KO | 1 | Neutral |
| Regeneron Pharmaceuticals REGN | -4 | Neutral |
| AbbVie Inc. ABBV | -7 | Neutral |
| Johnson & Johnson JNJ | -7 | Neutral |
| Mondelez International MDLZ | -11 | Neutral |
| Merck & Co. MRK | -11 | Neutral |
| Amgen Inc. AMGN | -14 | Neutral |
| Kroger Co. KR | -16 | Neutral |
| Costco Wholesale COST | -18 | Neutral |
| PepsiCo Inc. PEP | -21 | Neutral |
| Walmart Inc. WMT● you | -25 | Neutral |
| Abbott Laboratories ABT | -30 | Neutral |
| Pfizer Inc. PFE | -49 | Neutral |
| Thermo Fisher Scientific TMO | — | Neutral |
| Danaher Corp. DHR | — | Neutral |
| Intuitive Surgical Inc. ISRG | — | Neutral |
| Vertex Pharmaceuticals VRTX | — | Neutral |
| Gilead Sciences GILD | — | Neutral |
| Zoetis Inc. ZTS | — | Neutral |
| Kimberly-Clark Corp. KMB | — | Neutral |
| Hershey Co. HSY | — | Neutral |
| Sysco Corp. SYY | — | Neutral |
| Moderna Inc. MRNA | — | Neutral |
| Biogen Inc. BIIB | — | Neutral |
| DexCom Inc. DXCM | — | Neutral |
| Illumina Inc. ILMN | — | Neutral |
| HCA Healthcare HCA | — | Neutral |